In CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study), an IL-1β monoclonal antibody canakinumab was investigated in post-myocardial infarction (MI) patients with elevated high-sensitivity CRP (hsCRP). This evidence concerns the gene CRP and deep vein thrombosis.